The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.
May 16th 2024
Patients with HIV who switched to a treatment regimen that included tenofovir alafenamide (TAF) showed improvement in serum markers for hepatic steatosis (HS) among other benefits.
Collaborative, Multidisciplinary Care Has Positive Impact on Viral Suppression in HIV
October 3rd 2018Two studies presented at the 2018 Infectious Disease Week conference held in San Francisco, California, add to a pile of research demonstrating the positive impact of collaborative, multidisciplinary care in the HIV population, specifically on viral suppression.
Read More
Unstable Housing Has Adverse Impact on Viral Suppression, CD4 Cell Count in HIV Population
September 24th 2018Unstable housing among the HIV population is associated with decreased probability of viral suppression and adequate CD4 cell count. It also lowers the likelihood of mental health/counseling, visiting a healthcare provider, and engaging in continuity of care.
Read More
This Week in Managed Care: September 21, 2018
September 21st 2018This week, the top managed care news included the Senate overwhelmingly voting to ban pharmacist gag clauses; a study found the current vaccine pipeline for HIV, tuberculosis, and malaria may fall short; an expert noted a trend of healthcare cost data seeping into nonhealthcare companies’ earnings calls.
Watch
More Than 25% of HIV Providers Don't Know If Their State Expanded Medicaid
September 20th 2018A survey has revealed gaps in HIV providers’ knowledge of the Affordable Care Act. However, despite these gaps, the majority of surveyed providers expressed belief that Medicaid expansion would improve both HIV outcomes and general outcomes for patients with the disease.
Read More
Launch of Highly Efficacious HIV, Tuberculosis, and Malaria Vaccines Unlikely, Study Says
September 18th 2018Researchers determined that the current drug pipeline is unlikely to produce any highly effective vaccines for HIV, tuberculosis, or malaria, which could be important for controlling the spread of these diseases.
Read More
Medication Adherence Program for HIV Needs Collaboration Among Physicians, Nurses, and Pharmacists
September 15th 2018A descriptive, observational study in Switzerland implemented an interprofessional medication adherence program (IMAP) in patients with HIV. The framework for the implementation of services in pharmacy (FISpH) model is described and formulated for other healthcare facilities and professionals to evaluate and execute for themselves.
Read More
HIV/AIDS Research Has Positive Impacts Across Other Medical Fields
September 6th 2018In addition to the advances made in the HIV space, such as antiretroviral therapies and pre-exposure prophylaxis, the years of research has translated into advances outside the HIV field, including in oncology and other immune diseases.
Read More
Report: States Can Improve HIV Care Through Medicaid, Ryan White Program Collaboration
September 6th 2018In a 3-part series, the National Academy for State Health Policy explored how states can use policy levers to more effectively utilize limited resources and provide better care, improve care coordination services, and ensure consistent access to care for people living with HIV.
Read More
Closing Treatment Gaps Critical for Ending HIV Epidemic in United States
August 30th 2018Targeted treatment interventions for populations with low levels of viral suppression, paired with tailored prevention packages, will be essential to ending the HIV epidemic in the United States, say researchers.
Read More
Among HIV-positive Medicaid patients with comorbid medical and psychiatric disorders, there was increased outpatient service utilization, yet relative cost savings, for patients who were treated in patient-centered medical homes.
Read More
Putting AIDS 2018 Into Perspective: Policy, Advocacy Implications
August 15th 2018Contrasting the excitement and optimism coming out of clinical research presented at the AIDS 2018 conference, there was a sobering takeaway in the political and advocacy sphere. Among the general consensus that we are in a fragile moment in time, there were several policies and advocacy efforts that made it to the forefront of the conference.
Read More
Putting AIDS 2018 Into Perspective: Clinical Implications
August 14th 2018The 2018 International AIDS Conference in Amsterdam brought a plethora of new clinical implications for HIV care, reflecting ongoing investments in research efforts and optimism across all clinical domains, including vaccines, prevention, and new treatment approaches. However, with the excitement also came caution in other areas, such as stagnant incidence rates.
Read More
PEPFAR, Elton John Reaffirm Commitment to, Investment in HIV Support for Key Populations
August 3rd 2018During the 2018 International AIDS Conference, the US President’s Emergency Plan for AIDS Relief (PEPFAR) and the Elton John AIDS Foundation revealed initial results from the LGBT Fund, which they launched in 2016. PEPFAR also announced over $360 million in funding over the next 12 months.
Read More
This Week in Managed Care: July 27, 2018
July 27th 2018This week, the top managed care stories included CMS reversing its decision to suspend the risk adjustment payment program; out-of-pocket costs and copayment accumulators put an HIV prevention drug out of reach for patients; research finds geography can determine posttreatment imaging for women with breast cancer.
Watch
HIV Comorbidities Associated With More Hospitalizations, Increased Costs
July 26th 2018As people living with HIV now have a normal life expectancy, thanks to antiretroviral therapy, the burden of comorbidities is on the rise, and more than half of deaths in the patient population are attributable to these comorbidities.
Read More
Urgent Change in Approach to HIV Pandemic Is Needed, Report Says
July 20th 2018According to a report, existing HIV tools and strategies are insufficient, and despite historic breakthroughs in maximizing prevention and treatment strategies, the HIV pandemic will likely continue to be a global challenge for the foreseeable future.
Read More
FDA Approves First Darunavir-Based Single-Tablet Regimen for HIV
July 18th 2018Janssen announced the approval of Symtuza (darunavir 800 mg, cobistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) for the treatment of HIV-1 in treatment-naïve and certain virologically suppressed patients.
Read More